Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 5, 2014, Pages 950-959

  Ummanni, Ramesh ^a,c   Mannsperger, Heiko A ^a   Sonntag, Johanna ^a   Oswald, Marcus ^a,b,d   Sharma, Ashwini K ^a,b,d   König, Rainer ^b   Korf, Ulrike ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Biomarker; Cancer genetics; NSCLC; Reverse phase protein arrays; RPPA; Targeted proteomics

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; TOZASERTIB; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CELL; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE PHASE PROTEIN ARRAY; SIGNAL TRANSDUCTION;

BIOMARKER; CANCER GENETICS; NSCLC; REVERSE PHASE PROTEIN ARRAYS; RPPA; TARGETED PROTEOMICS;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84898599875     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.11.017     Document Type: Article

References (52)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. W.K. Lam, N.W. White, and M.M. Chan-Yeung Lung cancer epidemiology and risk factors in Asia and Africa Int. J. Tuberc. Lung. Dis. 8 2004 1045 1057 (Pubitemid 39201249)
3. M.J. Thun, L.M. Hannan, L.L. Adams-Campbell, P. Boffetta, J.E. Buring, D. Feskanich, W.D. Flanders, S.H. Jee, K. Katanoda, L.N. Kolonel, I.M. Lee, T. Marugame, J.R. Palmer, E. Riboli, T. Sobue, E. Avila-Tang, L.R. Wilkens, and J.M. Samet Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies PLoS Med. 5 2008 e185
4. R. Salgia, and A.T. Skarin Molecular abnormalities in lung cancer J. Clin. Oncol. 16 1998 1207 1217 (Pubitemid 28108759)
5. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N. Engl. J. Med. 359 2008 1367 1380
6. P.A. Janne, J.A. Engelman, and B.E. Johnson Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J. Clin. Oncol. 23 2005 3227 3234 (Pubitemid 46211347)
7. R. Feld, S.S. Sridhar, F.A. Shepherd, J.A. Mackay, and W.K. Evans C. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based, use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review J. Thorac. Oncol. 1 2006 367 376 (Pubitemid 47163993)
8. F. Cappuzzo, F.R. Hirsch, E. Rossi, S. Bartolini, G.L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W.A. Franklin, L. Crino, P.A. Bunn Jr., and M. Varella-Garcia Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J. Natl. Cancer Inst. 97 2005 643 655 (Pubitemid 40812628)
9. G.C. Chang, C.M. Tsai, K.C. Chen, C.J. Yu, J.Y. Shih, T.Y. Yang, C.P. Lin, J.Y. Hsu, C.H. Chiu, R.P. Perng, P.C. Yang, and C.H. Yang Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients J. Thorac. Oncol. 1 2006 520 525
10. F.R. Hirsch, and P.A. Bunn Jr. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J. Clin. Oncol. 23 2005 9044 9047
11. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139 (Pubitemid 38637993)
12. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
13. M.L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stuckrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W.F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenfuhrer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B.A. Weir, T.H. Chen, H. Greulich, J. Barretina, G.I. Shapiro, L.A. Garraway, A.F. Gazdar, J.D. Minna, M. Meyerson, K.K. Wong, and R.K. Thomas Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions J. Clin. Invest. 119 2009 1727 1740
14. M.L. Sos, and R.K. Thomas Systematically linking drug susceptibility to cancer genome aberrations Cell Cycle 8 2009 3652 3656
15. R. Tibes, Y. Qiu, Y. Lu, B. Hennessy, M. Andreeff, G.B. Mills, and S.M. Kornblau Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells Mol. Cancer Ther. 5 2006 2512 2521 (Pubitemid 44650915)
16. B.T. Hennessy, Y. Lu, A.M. Gonzalez-Angulo, M.S. Carey, S. Myhre, Z. Ju, M.A. Davies, W. Liu, K. Coombes, F. Meric-Bernstam, I. Bedrosian, M. McGahren, R. Agarwal, F. Zhang, J. Overgaard, J. Alsner, R.M. Neve, W.L. Kuo, J.W. Gray, A.L. Borresen-Dale, and G.B. Mills A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers Clin. Proteomics 6 2010 129 151
17. C.P. Paweletz, L. Charboneau, V.E. Bichsel, N.L. Simone, T. Chen, J.W. Gillespie, M.R. Emmert-Buck, M.J. Roth, I.E. Petricoin, and L.A. Liotta Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Oncogene 20 2001 1981 1989 (Pubitemid 32458030)
18. M. Pawlak, E. Schick, M.A. Bopp, M.J. Schneider, P. Oroszlan, and M. Ehrat Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis Proteomics 2 2002 383 393 (Pubitemid 34429356)
19. J.D. Wulfkuhle, J.A. Aquino, V.S. Calvert, D.A. Fishman, G. Coukos, L.A. Liotta, and E.F. Petricoin III Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays Proteomics 3 2003 2085 2090 (Pubitemid 37414073)
20. S. Nishizuka, L. Charboneau, L. Young, S. Major, W.C. Reinhold, M. Waltham, H. Kouros-Mehr, K.J. Bussey, J.K. Lee, V. Espina, P.J. Munson, E. Petricoin III, L.A. Liotta, and J.N. Weinstein Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays Proc. Natl. Acad. Sci. U. S. A. 100 2003 14229 14234 (Pubitemid 37499219)
21. C. Loebke, H. Sueltmann, C. Schmidt, F. Henjes, S. Wiemann, A. Poustka, and U. Korf Infrared-based protein detection arrays for quantitative proteomics Proteomics 7 2007 558 564 (Pubitemid 46362619)
22. L. Zhang, Q. Wei, L. Mao, W. Liu, G.B. Mills, and K. Coombes Serial dilution curve: a new method for analysis of reverse phase protein array data Bioinformatics 25 2009 650 654
23. H.A. Mannsperger, S. Gade, F. Henjes, T. Beissbarth, and U. Korf RPPanalyzer: analysis of reverse-phase protein array data Bioinformatics 26 2010 2202 2203
24. S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He, E. Barillot, T. Dubois, P. Hupe, and L. de Koning NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data PLoS One 7 2012 e38686
25. B. Spurrier, S. Ramalingam, and S. Nishizuka Reverse-phase protein lysate microarrays for cell signaling analysis Nat. Protoc. 3 2008 1796 1808
26. H.A. Mannsperger, S. Uhlmann, C. Schmidt, S. Wiemann, O. Sahin, and U. Korf RNAi-based validation of antibodies for reverse phase protein arrays Proteome Sci. 8 2010 69
27. R.K. Thomas, B. Weir, and M. Meyerson Genomic approaches to lung cancer Clin. Cancer Res. 12 2006 4384s 4391s (Pubitemid 44197186)
28. B. Schwanhausser, D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J. Wolf, W. Chen, and M. Selbach Global quantification of mammalian gene expression control Nature 473 2011 337 342
29. U. Korf, S. Derdak, A. Tresch, F. Henjes, S. Schumacher, C. Schmidt, B. Hahn, W.D. Lehmann, A. Poustka, T. Beissbarth, and U. Klingmuller Quantitative protein microarrays for time-resolved measurements of protein phosphorylation Proteomics 8 2008 4603 4612
30. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehar, G.V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M.F. Berger, J.E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jane-Valbuena, F.A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I.H. Engels, J. Cheng, G.K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M.D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R.C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J.P. Mesirov, S.B. Gabriel, G. Getz, K. Ardlie, V. Chan, V.E. Myer, B.L. Weber, J. Porter, M. Warmuth, P. Finan, J.L. Harris, M. Meyerson, T.R. Golub, M.P. Morrissey, W.R. Sellers, R. Schlegel, and L.A. Garraway The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
31. D.R. Xu, S. Huang, Z.J. Long, J.J. Chen, Z.Z. Zou, J. Li, D.J. Lin, and Q. Liu Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells J. Transl. Med. 9 2011 74
32. S. Medves, and J.B. Demoulin Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies J. Cell. Mol. Med. 16 2012 237 248
33. G.V. Scagliotti, and S. Novello The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors Cancer Treat. Rev. 38 2012 292 302
34. E. Castellano, and J. Downward RAS interaction with PI3K: more than just another effector pathway Genes Cancer 2 2011 261 274
35. L.V. Sequist, D.W. Bell, T.J. Lynch, and D.A. Haber Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer J. Clin. Oncol. 25 2007 587 595 (Pubitemid 350002967)
36. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
37. M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J.M. Heuckmann, M. Koker, S. Heynck, I. Stuckrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K.A. Politi, S. Perera, M. Getlik, L.C. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K.M. Shokat, W.R. Sellers, D. Rauh, C. Orr, K.P. Hoeflich, L. Friedman, K.K. Wong, W. Pao, and R.K. Thomas Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc. Natl. Acad. Sci. U. S. A. 106 2009 18351 18356
38. B.S. Hendriks, H.S. Wiley, and D. Lauffenburger HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms Biophys. J. 85 2003 2732 2745 (Pubitemid 37210819)
39. O. Sahin, H. Frohlich, C. Lobke, U. Korf, S. Burmester, M. Majety, J. Mattern, I. Schupp, C. Chaouiya, D. Thieffry, A. Poustka, S. Wiemann, T. Beissbarth, and D. Arlt Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance BMC Syst. Biol. 3 2009 1
40. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D.M. Muzny, M.B. Morgan, L. Fulton, R.S. Fulton, Q. Zhang, M.C. Wendl, M.S. Lawrence, D.E. Larson, K. Chen, D.J. Dooling, A. Sabo, A.C. Hawes, H. Shen, S.N. Jhangiani, L.R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S.E. Scherer, K. Clerc, G.A. Metcalf, B. Ng, A. Milosavljevic, M.L. Gonzalez-Garay, J.R. Osborne, R. Meyer, X. Shi, Y. Tang, D.C. Koboldt, L. Lin, R. Abbott, T.L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B.H. Dunford-Shore, A. Kraja, S.D. Crosby, C.S. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L.R. Chirieac, A. Dutt, T. Fennell, M. Hanna, B.E. Johnson, R.C. Onofrio, R.K. Thomas, G. Tonon, B.A. Weir, X. Zhao, L. Ziaugra, M.C. Zody, T. Giordano, M.B. Orringer, J.A. Roth, M.R. Spitz, I.I. Wistuba, B. Ozenberger, P.J. Good, A.C. Chang, D.G. Beer, M.A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W.D. Travis, W. Pao, M.A. Province, G.M. Weinstock, H.E. Varmus, S.B. Gabriel, E.S. Lander, R.A. Gibbs, M. Meyerson, and R.K. Wilson Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
41. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res. 61 2001 3986 3997 (Pubitemid 32720961)
42. B. Karakas, K.E. Bachman, and B.H. Park Mutation of the PIK3CA oncogene in human cancers Br. J. Cancer 94 2006 455 459 (Pubitemid 43289745)
43. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004
44. E.S. Park, R. Rabinovsky, M. Carey, B.T. Hennessy, R. Agarwal, W. Liu, Z. Ju, W. Deng, Y. Lu, H.G. Woo, S.B. Kim, J.H. Cheong, L.A. Garraway, J.N. Weinstein, G.B. Mills, J.S. Lee, and M.A. Davies Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set Mol. Cancer Ther. 9 2010 257 267
45. F. Wang, S. Wang, Z. Wang, J. Duan, T. An, J. Zhao, H. Bai, and J. Wang C. Key Laboratory of R. Translational, Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR J. Exp. Clin. Cancer Res. 31 2012 65
46. K. Stemke-Hale, A.M. Gonzalez-Angulo, A. Lluch, R.M. Neve, W.L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, W.F. Symmans, L. Pusztai, L.K. Nolden, H. Horlings, K. Berns, M.C. Hung, M.J. van de Vijver, V. Valero, J.W. Gray, R. Bernards, G.B. Mills, and B.T. Hennessy An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res. 68 2008 6084 6091
47. C.H. Heldin, K. Miyazono, and P. ten Dijke TGF-beta signalling from cell membrane to nucleus through SMAD proteins Nature 390 1997 465 471 (Pubitemid 28013118)
48. M.P. de Caestecker, E. Piek, and A.B. Roberts Role of transforming growth factor-beta signaling in cancer J. Natl. Cancer Inst. 92 2000 1388 1402
49. A. Damalas, S. Kahan, M. Shtutman, A. Ben-Ze'ev, and M. Oren Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation EMBO J. 20 2001 4912 4922 (Pubitemid 32848643)
50. M.P. Ebert, J. Yu, J. Hoffmann, A. Rocco, C. Rocken, S. Kahmann, O. Muller, M. Korc, J.J. Sung, and P. Malfertheiner Loss of beta-catenin expression in metastatic gastric cancer J. Clin. Oncol. 21 2003 1708 1714 (Pubitemid 46638581)
51. K.R. Calvo, L.A. Liotta, and E.F. Petricoin Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy Biosci. Rep. 25 2005 107 125 (Pubitemid 41437713)
52. X.F. Huang, S.K. Luo, J. Xu, J. Li, D.R. Xu, L.H. Wang, M. Yan, X.R. Wang, X.B. Wan, F.M. Zheng, Y.X. Zeng, and Q. Liu Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia Blood 111 2008 2854 2865